Regeneron Pharmaceuticals Management
Management criteria checks 4/4
Regeneron Pharmaceuticals' CEO is Leonard Schleifer, appointed in Jan 1988, has a tenure of 36.33 years. total yearly compensation is $8.18M, comprised of 22.9% salary and 77.1% bonuses, including company stock and options. directly owns 2.24% of the company’s shares, worth $2.37B. The average tenure of the management team and the board of directors is 6.7 years and 17.4 years respectively.
Key information
Leonard Schleifer
Chief executive officer
US$8.2m
Total compensation
| CEO salary percentage | 22.9% |
| CEO tenure | 36.3yrs |
| CEO ownership | 2.2% |
| Management average tenure | 6.7yrs |
| Board average tenure | 17.4yrs |
Recent management updates
Recent updates
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing
Apr 30
Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?
Apr 10Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
Mar 26Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings
Feb 16Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024
Feb 10Regeneron's Push Into Obesity, Q4 2023 Earnings Review
Feb 02These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
Jan 31Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?
Oct 25Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 52% Above Its Share Price
Aug 07Regeneron Pharmaceuticals (NASDAQ:REGN) Has A Pretty Healthy Balance Sheet
Jul 17Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?
Apr 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$8m | US$2m | US$4b |
| Sep 30 2023 | n/a | n/a | US$4b |
| Jun 30 2023 | n/a | n/a | US$4b |
| Mar 31 2023 | n/a | n/a | US$4b |
| Dec 31 2022 | US$7m | US$2m | US$4b |
| Sep 30 2022 | n/a | n/a | US$5b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$8b |
| Dec 31 2021 | US$6m | US$2m | US$8b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$4b |
| Dec 31 2020 | US$135m | US$1m | US$4b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$3b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$21m | US$1m | US$2b |
| Sep 30 2019 | n/a | n/a | US$2b |
| Jun 30 2019 | n/a | n/a | US$2b |
| Mar 31 2019 | n/a | n/a | US$2b |
| Dec 31 2018 | US$27m | US$1m | US$2b |
| Sep 30 2018 | n/a | n/a | US$2b |
| Jun 30 2018 | n/a | n/a | US$2b |
| Mar 31 2018 | n/a | n/a | US$1b |
| Dec 31 2017 | US$27m | US$1m | US$1b |
Compensation vs Market: Leonard's total compensation ($USD8.18M) is below average for companies of similar size in the US market ($USD13.62M).
Compensation vs Earnings: Leonard's compensation has been consistent with company performance over the past year.
CEO
Leonard Schleifer (70 yo)
36.3yrs
Tenure
US$8,184,338
Compensation
Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 36.3yrs | US$8.18m | 2.24% $ 2.4b | |
| Co-Founder | 23.3yrs | US$7.76m | 1.21% $ 1.3b | |
| Executive Vice President of Research | 5.3yrs | US$8.43m | 0.049% $ 51.4m | |
| Executive VP and GM of Industrial Operations & Product Supply | 16.1yrs | US$8.76m | 0.031% $ 33.1m | |
| Senior VP of Finance & CFO | less than a year | no data | 0.023% $ 23.9m | |
| Senior Vice President of Quality Assurance & Operations | 4.3yrs | no data | no data | |
| Senior VP of IT & Chief Information Officer | 3.3yrs | no data | no data | |
| Senior Vice President of Investor Relations & Strategic Analysis | no data | no data | no data | |
| Executive VP | 12.7yrs | US$7.13m | 0.037% $ 39.4m | |
| Senior VP & Chief Compliance Officer | 1.3yrs | no data | no data | |
| Senior Vice President of Corporate Affairs | no data | no data | no data | |
| Executive Vice President of Human Resources | 8.1yrs | no data | no data |
6.7yrs
Average Tenure
63.5yo
Average Age
Experienced Management: REGN's management team is seasoned and experienced (6.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 36.3yrs | US$8.18m | 2.24% $ 2.4b | |
| Co-Founder | 23.3yrs | US$7.76m | 1.21% $ 1.3b | |
| Lead Independent Director | 13.5yrs | US$748.01k | 0.00073% $ 769.8k | |
| Independent Director | 21.3yrs | US$724.99k | 0.017% $ 17.8m | |
| Independent Director | 32.9yrs | US$728.99k | 0.012% $ 12.3m | |
| Independent Director | 32.9yrs | US$709.99k | 0.0046% $ 4.9m | |
| Independent Director | 36.3yrs | US$724.99k | 0.026% $ 27.9m | |
| Independent Director | 7.3yrs | US$704.99k | 0.000010% $ 10.5k | |
| Independent Director | 1.6yrs | US$247.79k | 0.00042% $ 442.9k | |
| Independent Director | 7.7yrs | US$714.99k | 0% $ 0 | |
| Independent Director | 7.7yrs | US$709.99k | 0.0013% $ 1.3m | |
| Independent Director | less than a year | US$1.03m | no data |
17.4yrs
Average Tenure
70yo
Average Age
Experienced Board: REGN's board of directors are seasoned and experienced ( 17.4 years average tenure).